Bibliographic Details
| Title: |
Comprehensive approaches in Alzheimer’s disease: from general aspects to stem cell therapy and antidiabetic use. |
| Alternate Title: |
Enfoques integrales en la enfermedad de Alzheimer: desde aspectos generales hasta la terapia con células madre y el uso de antidiabéticos. |
| Authors: |
Murguiondo-Pérez, Renata1, Bautista-Gonzalez, Maria F.1, Cano-Herrera, Gabriela2, Méndez-Vionet, Amairani3, Vargas-Sánchez, Montserrat1, Vélez-Rodríguez, Ignacio4, Torres-Jiménez, María J.1, Garibaldi-Bernot, Franco1, Esparza Salazar, Felipe1,5 felipe.esparzas69@anahuac.mx |
| Source: |
Revista Mexicana de Neurociencia. May/Jun2025, Vol. 26 Issue 3, p95-102. 8p. |
| Subjects: |
NEURAL stem cells, STEM cell treatment, INSULIN resistance, TAU proteins, HYPOGLYCEMIC agents |
| Abstract (English): |
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-ß and Tau protein in brain tissue. AD represents 80% of the cases of dementia worldwide, affecting more than 7.29 million people with an increase in incidence of 147.95% in the past 30 years. At present, conventional treatments for this condition remain limited, which has led to a significant increase in its incidence and prevalence. In this paper, we address general aspects regarding AD, from its pathophysiology, diagnostic methods, and its association with insulin resistance; as well as present treatments and new alternatives, specifically hypoglycemic agents, such as metformin, liraglutide and insulin; and neural stem cells. It is concluded that stem cell and antidiabetic treatments had positive results in preclinical studies, so more future studies are required to consider them safe in humans. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): |
La AD es una enfermedad neurodegenerativa progresiva caracterizada por la acumulación de placas de Aß y de proteína Tau en el tejido cerebral. La AD representa el 80% de las etiologías de demencia afectando a más de 7.29 millones de personas con un incremento del 147.95% en su incidencia. Actualmente los tratamientos convencionales para esta condición siguen siendo limitados, lo que ha conllevado al aumento en su incidencia y prevalencia. En este texto abordamos generalidades de AD, desde su fisiopatología, métodos diagnósticos y su relación con la resistencia a la insulina; así como tratamientos actuales y nuevas alternativas, específicamente hipoglucemiantes como la metformina, liraglutida y la insulina, y células madre neurales. Se concluye que los tratamientos con células madre y antidiabéticos tuvieron resultados positivos en estudios preclínicos, por lo que se requieren más estudios futuros para poder considerarlos seguros en humanos. [ABSTRACT FROM AUTHOR] |
|
Copyright of Revista Mexicana de Neurociencia is the property of Academia Mexicana de Neurologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
MedicLatina |
